Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A open-label, global, multi-center Phase Ib clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of IMDELLTRA and YL201 combination regimen in ES-SCLC patients

Next Previous
X
Search
Trial Profile

A open-label, global, multi-center Phase Ib clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of IMDELLTRA and YL201 combination regimen in ES-SCLC patients

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tarlatamab (Primary) ; YL 201 (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Amgen

    • Most Recent Events

    • 11 Oct 2024 New trial record
    • 07 Oct 2024 According to a MediLink Therapeutics media release, the company announced a global clinical trial collaboration and supply agreement with Amgen Inc. Amgen will lead this trial and MediLink will provide the investigational drug YL201 for the combination study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top